Revised labels for epilepsy drugs obtain FDA clearance

05/5/2009 | Wall Street Journal, The

The FDA approved updated warning labels for epilepsy drugs, including Johnson & Johnson's Topamax, GlaxoSmithKline's Lamictal, and Novartis' Tegretol and Trileptal, that include information about a higher risk of suicidal tendencies. The agency said it is in talks with the companies about creating medication guides that educate patients about behavioral effects linked to the products.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC